Mammaglobin in peripheral blood and the tumor of breast cancer patients

Bozhenko, K. V.; Харченко, Н В; Васкевич, Е. Ф.; Кудинова, Е А; Ооржак, А В; Ni, Rozhkova; Троценко, И Д

doi:10.1134/s1990750816010030

Cited by 4 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 29 articles, 23-25,28,59,60,68,73,79,80,85,89,92,95,96,99,103,105,108,109,115,117,119,121,126,128,129,136,141 sensitivity and specificity were reported individually for a single biomarker. In 21 of these, sensitivity was greater than 70%.…”

Section: Discussionmentioning

confidence: 99%

Cancer Biomarkers in Liquid Biopsy for Early Detection of Breast Cancer: A Systematic Review

Duque

Manterola

Otzen

et al. 2022

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background: Breast cancer (BC) is the most common neoplasm in women worldwide. Liquid biopsy (LB) is a non-invasive diagnostic technique that allows the analysis of biomarkers in different body fluids, particularly in peripheral blood and also in urine, saliva, nipple discharge, volatile respiratory fluids, nasal secretions, breast milk, and tears. The objective was to analyze the available evidence related to the use of biomarkers obtained by LB for the early diagnosis of BC. Methods: Articles related to the use of biomarkers for the early diagnosis of BC due to LB, published between 2010 and 2022, from the databases (WoS, EMBASE, PubMed, and SCOPUS) were included. The MInCir diagnostic scale was applied in the articles to determine their methodological quality (MQ). Descriptive statistics were used, as well as determination of weighted averages of each variable, to analyze the extracted data. Sensitivity, specificity, and area under the curve values for specific biomarkers (individual or in panels) are described. Results: In this systematic review (SR), 136 articles met the selection criteria, representing 17 709 patients with BC. However, 95.6% were case-control studies. In 96.3% of cases, LB was performed in peripheral blood samples. Most of the articles were based on microRNA (miRNA) analysis. The mean MQ score was 25/45 points. Sensitivity, specificity, and area under the curve values for specific biomarkers (individual or in panels) have been found. Conclusions: The determination of biomarkers through LB is a useful mechanism for the diagnosis of BC. The analysis of miRNA in peripheral blood is the most studied methodology. Our results indicate that LB has a high sensitivity and specificity for the diagnosis of BC, especially in early stages.

show abstract

Section: Discussionmentioning

confidence: 99%

Cancer Biomarkers in Liquid Biopsy for Early Detection of Breast Cancer: A Systematic Review

Duque

Manterola

Otzen

et al. 2022

Clin Med Insights Oncol

View full text Add to dashboard Cite

show abstract

“…MGB is a member of the secretoglobin family of protein with a predicted molecular weight of 10 kD cloned from breast cancer epithelial cells [5]. The protein has been suggested as a tumor-associated marker for the diagnosis of breast carcinoma [6]. GCDFP-15 and mammaglobin are positively expressed in approximately 50% and 75% of breast carcinomas, respectively; but their sensitivity remains poor, particularly in high-grade breast cancer such as triple-negative breast carcinoma [3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological significance of Sox10 expression in triple-negative breast carcinoma

Jin¹,

Qin²,

Qi³

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose The present study aimed to investigate the Sox10 expression in the pathological diagnosis of triple-negative breast cancer (TNBC). Furthermore, its correlation with the clinicopathological characteristics and disease-free survival rate in patients with TNBC was also evaluated to identify the diagnostic utility of Sox10 as a reliable biomarker for diagnosis and prognosis of TNBC. Methods Using immunohistochemistry, we identified the expression of Sox10, GATA-3, FOXA1, GCDFP15 and MGB in 376 cases of primary invasive breast cancer, and 77 cases of metastatic breast cancer. The expression of Sox10 in different molecular subtypes of primary invasive breast cancer and metastatic breast cancer were also compared. Furthermore, the correlation between Sox10 expression and clinicopathological parameters and disease-free survival (DFS) of patients with primary TNBC were also analyzed. Results Expression of Sox10 was only detected in the myoepithelial cells of normal breast, but not in any other types of cells, including luminal cell and fibroblasts. The positive rate of Sox10 in primary and metastatic TNBC was significantly higher than that in the other two types (P < 0.001, P < 0.001, respectively). The sensitivity and specificity of Sox10 expression in primary TNBC and metastatic TNBC were significantly lower than GATA-3, significantly higher than FOXA1, GCDFP15, and MGB (P < 0.001, P = 0.0004, P = 0.0064, P = 0.0229, respectively). In 71 cases of primary TNBC, a higher expression rate of Sox10 was significantly associated with high-grade tumors, late-stage tumors, and tumors with involvement of four or more lymph node metastases (P = 0.0145, P = 0.0105, P = 0.0249, respectively). Conclusion Sox10 may be used as a novel reliable putative marker for the diagnosis of TNBC. Notably, Sox10 combined with GATA-3 expression may serve as a supplementary differential diagnostic biomarker for primary and metastatic TNBC. Besides, Sox10 may be a good predictor of the prognosis of primary and metastatic TNBC. This study also highlights the significance of targeting Sox10 as a promising potential therapeutic target gene for TNBC therapy.

show abstract

“…[7] have stated that MGB is overexpressed in breast carcinoma as compared to the normal breast epithelium' and that it 'can act as a useful tool in the diagnosis of women with breast cancer. Although being highly expressed in the early stages of breast cancer, MGB-A expression has been shown to decrease during the progression of this disease [8], thus pointing towards a poorer prognosis.…”

mentioning

confidence: 99%

Microvessel Density and Mammaglobin A Expression as Prognostic Markers in Molecular Types of Breast Cancer

Jitariu¹,

Ceauşu²,

Meche³

et al. 2019

Rev. Chim.

View full text Add to dashboard Cite

Increased microvessel density (MVD) values in breast cancer correlate with tumor growth and progression while mammaglobin (MGB) expression in tumor cells is associated with a favorable prognosis. We aim to evaluate and correlate MVD values with MGB expression in molecular types of breast cancer specimens and to determine their utility as prognostic biological markers. A number of 52 breast cancer specimens were included in the study. Specimens were processed for routine histopathological diagnosis followed by the molecular classification by means of estrogen (ER), progesterone (PR) and HER2 immunohistochemical reactions. After performing immunohistochemistry for CD34 and MGB, MVD evaluation was made using the �hot spot� method for each case and MGB was scored between 0 (negative) and +3 (strong positive) depending on the intensity and distribution of the staining. MGB expression in tumor cells and MVD mean values were extremely variable. The greatest MVD mean values were obtained in luminal B followed by HER2, luminal A and triple negative breast cancer (TNBC) (95.33, 69, 62, and 40, respectively). MGB expression in the tumor cells generally ranged from mild to weak and was strong only in a few invasive ductal carcinoma cases. In cases with TNBCs the expression of MGB in tumor cells was weak and focal or negative. This variability was noticed between the molecular types of breast cancers and even within the same molecular type. In a restricted number of cases, MGB positive tumors were associated with low MVD values while the negative cases were characterized by increased MVD mean values. The variable results we obtained regarding the correlation between MVD and MGB in breast cancer specimens may indicate a rather restricted use of MVD/MGB in estimating breast cancer patients� prognosis.

show abstract

Mammaglobin in peripheral blood and the tumor of breast cancer patients

Cited by 4 publications

References 9 publications

Cancer Biomarkers in Liquid Biopsy for Early Detection of Breast Cancer: A Systematic Review

Cancer Biomarkers in Liquid Biopsy for Early Detection of Breast Cancer: A Systematic Review

Clinicopathological significance of Sox10 expression in triple-negative breast carcinoma

Microvessel Density and Mammaglobin A Expression as Prognostic Markers in Molecular Types of Breast Cancer

Contact Info

Product

Resources

About